PACLITAXEL ACCORD paclitaxel 30 mg/5 mL concentrated injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

paclitaxel accord paclitaxel 30 mg/5 ml concentrated injection vial

accord healthcare pty ltd - paclitaxel -

DOCETAXEL ACCORD 80 mg/4 mL docetaxel concentrated injection 80 mg/4 mL glass vial Australia - English - Department of Health (Therapeutic Goods Administration)

docetaxel accord 80 mg/4 ml docetaxel concentrated injection 80 mg/4 ml glass vial

accord healthcare pty ltd - docetaxel, quantity: 80 mg - injection, concentrated - excipient ingredients: polysorbate 80; ethanol absolute; citric acid - breast cancer docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed. docetaxel in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy. docetaxel in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress her2 and who previously have not received chemotherapy for metastatic disease adjuvant treatment of breast cancer docetaxel in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with node-positive breast cancer. doxorubicin and cyclophosphamide followed by docetaxel in combination with trastuzumab (ac-th) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2. docetaxel in combination with carboplatin and trastuzumab (tch) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2 docetaxel in combination with cyclophosphamide is indicated for the adjuvant treatment of operable breast cancer with a primary tumour of = 1 cm and < 7 cm. non small cell lung cancer docetaxel is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer, including those who have failed platinum-based chemotherapy. ovarian cancer docetaxel is indicated for the treatment of metastatic carcinoma of the ovary after failure of first-line or subsequent chemotherapy. prostate cancer docetaxel is indicated for the treatment of patients with androgen independent (hormone refractory) prostate cancer. head and neck cancer docetaxel in combination with cisplatin and fluorouracil, is indicated as induction treatment prior to chemoradiotherapy, for the treatment of patients with locally advanced, squamous cell carcinoma of the head and neck, who have low probability of surgical cure, require organ preservation or where the tumour is technically unresectable.

DOCETAXEL ACCORD 20 mg/1 mL docetaxel concentrated injection 20 mg/1 mL glass vial Australia - English - Department of Health (Therapeutic Goods Administration)

docetaxel accord 20 mg/1 ml docetaxel concentrated injection 20 mg/1 ml glass vial

accord healthcare pty ltd - docetaxel -

DOCETAXEL ACCORD 160 mg/8 mL docetaxel concentrated injection 160 mg/8 mL glass vial Australia - English - Department of Health (Therapeutic Goods Administration)

docetaxel accord 160 mg/8 ml docetaxel concentrated injection 160 mg/8 ml glass vial

accord healthcare pty ltd - docetaxel, quantity: 160 mg - injection, concentrated - excipient ingredients: citric acid; ethanol absolute; polysorbate 80 - breast cancer docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed. docetaxel in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy. docetaxel in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress her2 and who previously have not received chemotherapy for metastatic disease adjuvant treatment of breast cancer docetaxel in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with node-positive breast cancer. doxorubicin and cyclophosphamide followed by docetaxel in combination with trastuzumab (ac-th) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2. docetaxel in combination with carboplatin and trastuzumab (tch) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2 docetaxel in combination with cyclophosphamide is indicated for the adjuvant treatment of operable breast cancer with a primary tumour of = 1 cm and < 7 cm. non small cell lung cancer docetaxel is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer, including those who have failed platinum-based chemotherapy. ovarian cancer docetaxel is indicated for the treatment of metastatic carcinoma of the ovary after failure of first-line or subsequent chemotherapy. prostate cancer docetaxel is indicated for the treatment of patients with androgen independent (hormone refractory) prostate cancer. head and neck cancer docetaxel in combination with cisplatin and fluorouracil, is indicated as induction treatment prior to chemoradiotherapy, for the treatment of patients with locally advanced, squamous cell carcinoma of the head and neck, who have low probability of surgical cure, require organ preservation or where the tumour is technically unresectable.

MIDAZOLAM ACCORD midazolam (as hydrochloride) 15 mg/3 mL solution for injection ampoules Australia - English - Department of Health (Therapeutic Goods Administration)

midazolam accord midazolam (as hydrochloride) 15 mg/3 ml solution for injection ampoules

accord healthcare pty ltd - midazolam, quantity: 15 mg - injection, solution - excipient ingredients: sodium hydroxide; water for injections; sodium chloride; hydrochloric acid - ? iv as an agent for conscious sedation prior to short surgical, diagnostic, therapeutic or endoscopic procedures, such as bronchoscopy, gastroscopy, cystoscopy, coronary angiography and cardiac catheterisation, either alone or in conjunction with a narcotic;,? iv for induction of anaesthesia, preliminary to administration of other anaesthetic agents. with the use of a narcotic premedicant, induction of anaesthesia can be attained with a narrower dose range and in a shorter period of time.,? iv for sedation in intensive care units; intermittent administration or continuous infusion.,? im for preoperative sedation (induction of sleepiness or drowsiness and relief of apprehension) and to impair memory of perioperative events.

MIDAZOLAM ACCORD midazolam (as hydrochloride) 5 mg/1 mL solution for injection ampoules Australia - English - Department of Health (Therapeutic Goods Administration)

midazolam accord midazolam (as hydrochloride) 5 mg/1 ml solution for injection ampoules

accord healthcare pty ltd - midazolam, quantity: 5 mg - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide; sodium chloride - ? iv as an agent for conscious sedation prior to short surgical, diagnostic, therapeutic or endoscopic procedures, such as bronchoscopy, gastroscopy, cystoscopy, coronary angiography and cardiac catheterisation, either alone or in conjunction with a narcotic;,? iv for induction of anaesthesia, preliminary to administration of other anaesthetic agents. with the use of a narcotic premedicant, induction of anaesthesia can be attained with a narrower dose range and in a shorter period of time.,? iv for sedation in intensive care units; intermittent administration or continuous infusion.,? im for preoperative sedation (induction of sleepiness or drowsiness and relief of apprehension) and to impair memory of perioperative events.

MIDAZOLAM ACCORD midazolam (as hydrochloride) 5 mg/ 5 mL solution for injection ampoules Australia - English - Department of Health (Therapeutic Goods Administration)

midazolam accord midazolam (as hydrochloride) 5 mg/ 5 ml solution for injection ampoules

accord healthcare pty ltd - midazolam, quantity: 5 mg - injection, solution - excipient ingredients: hydrochloric acid; sodium chloride; sodium hydroxide; water for injections - ? iv as an agent for conscious sedation prior to short surgical, diagnostic, therapeutic or endoscopic procedures, such as bronchoscopy, gastroscopy, cystoscopy, coronary angiography and cardiac catheterisation, either alone or in conjunction with a narcotic;,? iv for induction of anaesthesia, preliminary to administration of other anaesthetic agents. with the use of a narcotic premedicant, induction of anaesthesia can be attained with a narrower dose range and in a shorter period of time.,? iv for sedation in intensive care units; intermittent administration or continuous infusion.,? im for preoperative sedation (induction of sleepiness or drowsiness and relief of apprehension) and to impair memory of perioperative events.

MIDAZOLAM ACCORD midazolam (as hydrochloride) 50 mg/10 mL solution for injection ampoules Australia - English - Department of Health (Therapeutic Goods Administration)

midazolam accord midazolam (as hydrochloride) 50 mg/10 ml solution for injection ampoules

accord healthcare pty ltd - midazolam, quantity: 50 mg - injection, solution - excipient ingredients: sodium hydroxide; water for injections; hydrochloric acid; sodium chloride - ? iv as an agent for conscious sedation prior to short surgical, diagnostic, therapeutic or endoscopic procedures, such as bronchoscopy, gastroscopy, cystoscopy, coronary angiography and cardiac catheterisation, either alone or in conjunction with a narcotic;,? iv for induction of anaesthesia, preliminary to administration of other anaesthetic agents. with the use of a narcotic premedicant, induction of anaesthesia can be attained with a narrower dose range and in a shorter period of time.,? iv for sedation in intensive care units; intermittent administration or continuous infusion.,? im for preoperative sedation (induction of sleepiness or drowsiness and relief of apprehension) and to impair memory of perioperative events.

PACLITAXEL ACCORD paclitaxel 30 mg/5 mL concentrated injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

paclitaxel accord paclitaxel 30 mg/5 ml concentrated injection vial

accord healthcare pty ltd - paclitaxel, quantity: 30 mg - injection, concentrated - excipient ingredients: peg-35 castor oil; ethanol absolute - - primary treatment of ovarian cancer in combination with a platinum agent.. - treatment of metastatic carcinoma of the ovary after failure of standard therapy.. - treatment of metastatic carcinoma of the breast after failure of standard therapy.. - adjuvant treatment of node-positive breast cancer administered sequentially to doxorubicin and cyclophosphamide.. - treatment of metastatic cancer of the breast, in combination with trastuzumab (herceptin?), in patients who have tumours that over-express her-2 and who have not received previous chemotherapy for their metastatic disease.. - in combination with gemcitabine (gemzar?), is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. . - for the treatment of non-small cell lung cancer (nsclc).

PACLITAXEL ACCORD paclitaxel 100 mg/16.7 mL concentrated injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

paclitaxel accord paclitaxel 100 mg/16.7 ml concentrated injection vial

accord healthcare pty ltd - paclitaxel, quantity: 100 mg - injection, concentrated - excipient ingredients: ethanol absolute; peg-35 castor oil - - primary treatment of ovarian cancer in combination with a platinum agent.. - treatment of metastatic carcinoma of the ovary after failure of standard therapy.. - treatment of metastatic carcinoma of the breast after failure of standard therapy.. - adjuvant treatment of node-positive breast cancer administered sequentially to doxorubicin and cyclophosphamide.. - treatment of metastatic cancer of the breast, in combination with trastuzumab (herceptin?), in patients who have tumours that over-express her-2 and who have not received previous chemotherapy for their metastatic disease.. - in combination with gemcitabine (gemzar?), is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. . - for the treatment of non-small cell lung cancer (nsclc).